EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Regulatory news and changes

Which quality and handling changes affect quotations and continuity?

Dose Diligence research deskSection 04 · Page 8 of 17Last updated 17 Nov 2026

Are large multidose vials really several months of usable supply?

Not necessarily; the supported post-puncture use period must be reconciled with the prescription and label. FDA’s August 12 letter, published by Arizona’s Board of Nursing on September 8, addresses oversized compounded GLP-1 vials, confusing concentrations and instructions to continue use beyond the customary 28-day period. It recommends clear discard instructions and highlights dosing and contamination concerns. This is a safety communication, not a newly enacted universal vial-expiry statute. FDA letter hosted by the state board. (azbn.gov)

Recommended quote fields: unopened beyond-use date; post-puncture discard instruction; concentration; total volume; measuring device; shipment frequency; and who pays for unusable remainder. Do not treat all labelled milligrams as deliverable treatment supply. Have the pharmacist and medical director resolve conflicting instructions before the CFO models wastage.

What should buyers check about imported ingredients?

FDA’s Import Alert 66-80, displaying a publication date of October 9, 2026, concerns detention without physical examination of GLP-1 bulk substances and identifies green-list exceptions by manufacturer/product. Its current revision also addresses orforglipron materials. Import Alert 66-80. (accessdata.fda.gov)

Recommended evidence request: actual API manufacturer and site, relevant product identity, source-chain records and lot-specific certificates of analysis. Match the claimed green-list position to the actual manufacturer and substance—not merely the broker. FDA expressly says its border action does not create new limits on otherwise lawful compounding; border admissibility likewise should not be treated as product-specific compounding clearance. FDA GLP-1 concerns. (fda.gov)

FDA also distinguishes semaglutide sodium and acetate from the active ingredient in approved medicines and says it is unaware of a lawful compounding basis for those salts. Include exact ingredient identity in the supply-route screen. (fda.gov)

Sources cited on this page

  1. azbn.gov · Source 1 ↗https://azbn.gov/news/fda-safety-advisory-compounded-glp-1-multi-dose-vials
  2. accessdata.fda.gov · Source 2 ↗https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Section sources →